Navigation Links
Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
Date:10/29/2008

Franklin's Experience to Bring Growth and Leadership

CARY, N.C., Oct. 29 /PRNewswire/ -- Cornerstone Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that Josh Franklin has joined the company as vice president, Marketing.

Craig Collard, Cornerstone's president and chief executive officer, welcomed Franklin to the company, noting that "Josh's skills in pharmaceutical brand management and his leadership experience in a growth environment will be key as Cornerstone transitions into a publicly-held company." As announced in May Cornerstone plans to go public through a merger with Critical Therapeutics (Nasdaq: CRTX), which is scheduled to close in Q4 2008.

Before his Cornerstone appointment, Franklin was a key member of the marketing team at St. Louis, Mo.-based Ther-Rx Corporation (a subsidiary of KV Pharmaceutical) during a critical five-year growth period, serving most recently as vice president, Marketing. In previous positions, Franklin filled marketing roles with Biovail Pharmaceuticals and Ross Products Division, Abbott Labs. In these positions, he launched and managed products throughout various lifecycle phases in multiple therapeutic categories.

"I know I'm joining Cornerstone at a pivotal time," said Franklin, returning to North Carolina for the second time in his career. "And, I'm looking forward to helping lead not only the evolution of products and processes but also the company itself as our organization elevates to the next level."

A U.S. Army veteran, Mr. Franklin holds a B.S. in Business Administration from Methodist University, and M.H.A. and M.B.A. degrees from The Ohio State University.

ABOUT CORNERSTONE THERAPEUTICS, INC.

Cornerstone BioPharma Holdings, Inc., located in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone currently promotes four marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone's commercial strategy is to acquire non-promoted or underperforming branded pharmaceutical products and then maximize their potential value by promoting the products using its sales and marketing capabilities and applying various product life cycle management techniques. Cornerstone's product development pipeline consists of three line extensions of one of its currently marketed products and three other product candidates for the respiratory market. Cornerstone also generates revenue from the sale of six marketed product lines that include products that it does not promote.


'/>"/>
SOURCE Cornerstone Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
6. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
7. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
8. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
9. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
10. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
11. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... ... Outlook’s top Clinical Data Management Solution Providers list for its expertise in eClinical ... and domain expertise to serve the technology needs of global clients. DDi provides ...
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
(Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for certain ... Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
Breaking Medicine Technology: